EpiBiologics raised $107 million in a Series B co-led by GV and J&J’s venture arm to advance its surface protein-targeting degraders (EpiTACs) toward human testing in lung and head-and-neck cancers. The Bay Area startup plans first-in-human studies in H1 2026 and said its bispecific degrader EPI-326 targets tumor EGFR for selective lysosomal disposal. The financing attracted strategic names—Johnson & Johnson and Google’s GV—highlighting industry interest in targeted protein degradation approaches beyond intracellular small-molecule degraders. EpiBiologics says its approach may offer safety and combination advantages by precisely degrading tumor-expressed proteins while sparing healthy tissue. Investors and partners cited the modality’s potential to enable combination regimens and address resistance to existing targeted therapies. The round provides runway for IND filings and initial clinical cohorts.